Delivery Order 36C24E20D0028-36C24E24N0245
- Not listed
- The U.S. Department of Veterans Affairs has awarded a $6.3 million firm fixed-price delivery order to Infinity Biologix LLC for genomic analysis services. The award, issued on September 30, 2025, with an ultimate completion date of March 29, 2026, does not include a socioeconomic set-aside. Work will be performed in Washington, DC. Infinity Biologix LLC, a for-profit limited liability company based in Piscataway, New Jersey, operating through its Sampled Division, specializes in advanced...
- The U.S. federal government awarded a delivery order valued at $9.87 million to Infinity Biologix LLC for genomic analysis services. The contract, awarded on September 30, 2020, with a completion date of May 2, 2024, represents a firm fixed-price engagement with no socioeconomic set-aside designation. The work will be performed in Washington, DC, and the funding originates from a civilian federal agency. Infinity Biologix LLC, operating through its Sampled Division and based in Piscataway, New...
- Infinity Biologix LLC, operating through its Sampled Division and based in Piscataway, New Jersey, was awarded a delivery order for genomic analysis services valued at $1.6M under a firm fixed-price contract. The work will be performed in Boston, Massachusetts, with a completion target of September 29, 2025. This contract was awarded without a socioeconomic set-aside and represents a continuation of the company's established track record providing high-complexity genomic research services to...
- Infinity Biologix LLC, operating as the Sampled Division and based in Piscataway, New Jersey, was awarded a delivery order valued at $13.5 million for genomic analysis services. The contract, issued on September 30, 2021, with an ultimate completion date of September 29, 2022, carries firm fixed-price terms and was funded by a civilian federal agency headquartered in Washington, DC. No socioeconomic set-aside was applied to this award. The delivery order represents a continuation of Infinity...
- The U.S. government awarded a $6.3 million firm fixed-price delivery order for genomic analysis services to Infinity Biologix LLC (doing business as Sampled Division), a biomedical research company based in Piscataway, New Jersey. The contract, awarded on September 30, 2023, with an ultimate completion date of September 29, 2025, will be performed in Washington, DC and funded by a civilian federal agency. This delivery order represents no set-aside designation and is part of the company's...
- The Department of Veterans Affairs, Veterans Integrated Service Network 1 (VISN 1), awarded a delivery order to Infinity Biologix LLC for long read sequencing services with a ceiling value of $1.19M. The contract employs firm fixed-price pricing with an ultimate completion date of March 1, 2027, and work will be performed in Piscataway, New Jersey. This delivery order was issued without a set-aside designation and represents task ordering under an existing vehicle established with the VA....
- This federal contract was awarded by the Department of Health and Human Services' National Institutes of Health National Institute on Aging to Infinity Biologix LLC, a biorepository and laboratory services company, for DNA extraction and genotyping services. The contract is a firm fixed-price purchase order valued at $182,183.00, with a completion date of September 21, 2022. The contract does not have a set-aside designation. Infinity Biologix, through its Sampled division, has provided...
- This is a delivery order contract awarded by the National Institute on Drug Abuse (NIDA), a civilian agency, to Infinity Biologix LLC, doing business as Sampled Division. The $2,712,502.66 firm-fixed-price contract is for the NIDA Center for Genetic Studies, covering the period from March 14, 2025 to March 13, 2026. The contract does not have a set-aside designation. Infinity Biologix is a leading provider of genomic analysis, sequencing, DNA extraction, genotyping, and biorepository services to...
- The National Institute on Drug Abuse (NIDA) awarded a delivery order valued at $2.96 million to Infinity Biologix LLC for continued operation of the NIDA Center for Genetic Studies. This task order (75N95026F00001, designated TO4) runs from March 14, 2026 through March 13, 2027 and represents work performed at the contractor's facility in Piscataway, New Jersey. The award utilizes a firm-fixed-price contract structure with no socioeconomic set-aside and is part of a larger $15 million indefinite...
- This federal contract award was issued by the Department of Veterans Affairs (VA) to Illumina, Inc., a manufacturer of genetic and genomic analysis products and services. The $302,562.10 firm fixed price purchase order is for the supply of the INFINIUM MULTI-ETHNIC GLOBAL-8 V1.0 KIT (48 SAMPLES) to support the VA's genomic sequencing and analysis needs. This award is not associated with a set-aside. Illumina has previously received prime contract and subcontract awards from various federal...
- 36C24E20D0028Indefinite Delivery Contract
- 36C24E20D0028-36C24E24N0245Delivery Order
The U.S. Department of Veterans Affairs awarded a $4.4 million firm fixed-price delivery order to Infinity Biologix LLC for genomic analysis services, effective September 30, 2024, with completion targeted for September 29, 2025. Infinity Biologix, based in Piscataway, New Jersey, and operating through its Sampled Division, is a specialized biomedical research firm providing comprehensive genomic sequencing, DNA extraction, genotyping, and biorepository solutions to multiple federal agencies. This delivery order was awarded without a socioeconomic set-aside and will be performed in Washington, DC. The contract reflects the company's established capability as a provider of high-complexity laboratory and genomic research services across federal agencies including the National Institutes of Health, Centers for Disease Control and Prevention, and Department of Agriculture. Infinity Biologix's substantial federal contracting history demonstrates its technical capacity and experience in large-scale genomic initiatives, including notable prior work on COVID-19 SARS-2 sequencing across all 50 states. The company maintains significant indefinite delivery contracts with federal agencies, including a $149.2 million agreement with the National Cancer Institute for genome characterization services and a $15 million contract with the National Institute on Drug Abuse to support the NIDA Center for Genetic Studies. This delivery order represents continued engagement with the federal research community for critical genomic analysis support, aligning with the Department of Veterans Affairs' scientific research programs and medical initiatives.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| P00002 | Funding Only Action | ($46) | 3/15/26 | |
| P00001 | Other Administrative Action | $400.0k | 9/9/24 | |
| Not listed | Not listed | $4.0m | 9/5/24 |